IGF-1 promotes cellular growth, tissue repair, and muscle hypertrophy, while LR3, a longer-acting variant, increases the peptides bioavailability and prolongs its effects
AOD-9604s key advantage is extensive human safety data from clinical trials involving nearly 900 participants, establishing excellent tolerability
Unlike pharmaceutical sleep aids that cause next-day drowsiness, cognitive impairment, tolerance, and dependency, DSIP enhances sleep quality without sedative side effects, maintains normal sleep architecture, causes no morning grogginess, develops no tolerance requiring dose escalation, and demonstrates no withdrawal symptoms or addiction potential
Research-backed BPC-157 protocol for MCL knee injuries
Great for mood and can enhance our neurotransmitters: GABA, serotonin and dopamine